PERSPECTA

News from every angle

← Back to headlines

InspireMD Signals Potential FDA Decisions and Cost Savings

InspireMD has indicated potential FDA decisions in Q4 2026 and is targeting $9 million in annual cost savings.

17 Aug, 15:49 — 17 Aug, 15:49
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed1d ago

InspireMD signals potential FDA decisions in Q4 2026 while targeting $9M in annual cost savings

Read full article →

Related Stories

British Data Group Quantexa Considers UK or US IPO

36m ago

Xiaomi Reports Significant Profit Decline in Second Quarter

36m ago

State Farm Distributes $5 Billion Dividend to Auto Policyholders

45m ago

Global Borrowing Costs Reach New Highs Amid Bond Slump

56m ago